Arbutus Biopharma Corporation (NASDAQ:ABUS)‘s stock had its “buy” rating reissued by analysts at Chardan Capital in a report issued on Wednesday.

ABUS has been the topic of several other reports. Zacks Investment Research downgraded shares of Arbutus Biopharma Corporation from a “hold” rating to a “sell” rating in a report on Tuesday, July 4th. Ladenburg Thalmann Financial Services assumed coverage on shares of Arbutus Biopharma Corporation in a report on Friday, June 2nd. They set a “buy” rating and a $32.00 price objective on the stock. One investment analyst has rated the stock with a hold rating and five have given a buy rating to the stock. The company has an average rating of “Buy” and an average price target of $12.81.

Shares of Arbutus Biopharma Corporation (NASDAQ:ABUS) opened at 5.00 on Wednesday. The firm’s market cap is $275.13 million. The firm has a 50-day moving average of $3.96 and a 200 day moving average of $3.53. Arbutus Biopharma Corporation has a 52 week low of $2.35 and a 52 week high of $5.05.

ILLEGAL ACTIVITY NOTICE: This news story was originally posted by American Banking News and is the property of of American Banking News. If you are viewing this news story on another publication, it was stolen and republished in violation of United States and international copyright laws. The correct version of this news story can be viewed at https://www.americanbankingnews.com/2017/09/16/arbutus-biopharma-corporations-abus-buy-rating-reiterated-at-chardan-capital.html.

In other Arbutus Biopharma Corporation news, insider Michael J. Sofia sold 30,000 shares of the company’s stock in a transaction dated Tuesday, August 15th. The shares were sold at an average price of $3.70, for a total transaction of $111,000.00. Following the sale, the insider now directly owns 1,563,403 shares of the company’s stock, valued at $5,784,591.10. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. 10.00% of the stock is owned by corporate insiders.

Institutional investors have recently made changes to their positions in the company. Vanguard Group Inc. lifted its holdings in shares of Arbutus Biopharma Corporation by 2.7% in the second quarter. Vanguard Group Inc. now owns 77,413 shares of the biopharmaceutical company’s stock worth $279,000 after buying an additional 2,035 shares in the last quarter. OxFORD Asset Management LLP lifted its holdings in shares of Arbutus Biopharma Corporation by 89.9% in the second quarter. OxFORD Asset Management LLP now owns 83,310 shares of the biopharmaceutical company’s stock worth $300,000 after buying an additional 39,436 shares in the last quarter. Renaissance Technologies LLC lifted its holdings in shares of Arbutus Biopharma Corporation by 785.1% in the first quarter. Renaissance Technologies LLC now owns 124,573 shares of the biopharmaceutical company’s stock worth $405,000 after buying an additional 110,499 shares in the last quarter. Victory Capital Management Inc. purchased a new stake in shares of Arbutus Biopharma Corporation in the second quarter worth about $478,000. Finally, Bank of Montreal Can lifted its holdings in shares of Arbutus Biopharma Corporation by 1.9% in the second quarter. Bank of Montreal Can now owns 874,254 shares of the biopharmaceutical company’s stock worth $3,147,000 after buying an additional 16,535 shares in the last quarter. 67.06% of the stock is currently owned by hedge funds and other institutional investors.

Arbutus Biopharma Corporation Company Profile

Arbutus Biopharma Corporation, formerly Tekmira Pharmaceuticals Corporation, is a therapeutic solutions company. The Company is engaged in discovering, developing and commercializing a cure for patients suffering from chronic hepatitis B infection (HBV), a disease of the liver caused by the hepatitis B virus (HBV).

Analyst Recommendations for Arbutus Biopharma Corporation (NASDAQ:ABUS)

Receive News & Ratings for Arbutus Biopharma Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Arbutus Biopharma Corporation and related companies with MarketBeat.com's FREE daily email newsletter.